Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pharmacol Toxicol Methods. 2014 Jan-Feb;69(1):39-48. doi: 10.1016/j.vascn.2013.10.004. Epub 2013 Oct 20.

A bioactive probe for glutathione-dependent antioxidant capacity in breast cancer patients: implications in measuring biological effects of arsenic compounds.

Author information

1
Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood PA 19096 USA.
2
Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood PA 19096 USA; Department of Biological Sciences, Drexel University, Philadelphia, PA 19104, USA.
3
Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood PA 19096 USA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. Electronic address: iraayene@hotmail.com.

Abstract

INTRODUCTION:

Glutathione, a major cellular non-protein thiol (NPSH), serves a central role in repairing damage induced by cancer drugs, pollutants and radiation and in the detoxification of several cancer chemotherapeutic drugs and toxins. Current methods measure glutathione levels only, which require cellular extraction, rather than the glutathione recycling dependent antioxidant activity in intact cells. Here, we present a novel method using a bioactive probe of the oxidative pentose phosphate cycle, termed the OxPhos™ test, to quantify glutathione recycling dependent antioxidant activity in whole blood and intact human and rodent cells without the need for the isolation and cytoplasm extraction of cells.

METHODS:

OxPhos™ test kit (Rockland Immunochemicals, USA), which uses hydroxyethyldisulfide (HEDS) as a probe for the oxidative pentose phosphate cycle, was used in these studies. The results with OxPhos™ test kit in human blood and intact cells were compared with total thiol and high pressure liquid chromatography/electrochemical detection of HEDS metabolism.

RESULTS:

The OxPhos™ test measured glutathione-dependent antioxidant activity both in intact human and rodent cells and breast cancer patient's blood with a better correlation coefficient and biological variability than the thiol assay. Additionally, human blood and mammalian cells treated with various arsenicals showed a concentration-dependent decrease in activity.

DISCUSSION:

The results demonstrate the application of this test for measuring the antioxidant capacity of blood and the effects of environmental pollutants/toxins. It opens up new avenues for an easy and reliable assessment of glutathione-dependent antioxidant capacity in various diseases such as stroke, blood borne diseases, infection, cardiovascular disease and other oxidative stress related diseases and as a prognostic indicator of chemotherapy response and toxicity. The use of this approach in pharmacology/toxicology including screening drugs that improve the glutathione-dependent antioxidant capacity and not just the glutathione level is clinically relevant since mammalian cells require glutathione dependent pathways for antioxidant activity.

KEYWORDS:

Antioxidant activity; Arsenicals; Biomarker; Blood; DTNB; G6PD; GRase; GRx; GSH; GSSG; GST; Glutathione; Glutathione recycling; HEDS; Human cells; ME; NPSH; OPPC; OxPhos™ test; PSH; Total thiol; Toxins; dithiobisnitrobenzoic acid; glucose-6-phosphate dehydrogenase; glutaredoxin; glutathione; glutathione S-transferase; glutathione reductase; hydroxyethyldisulfide; mercaptoethanol; non-protein thiol; oxidative pentose phosphate cycle; oxidized glutathione; protein thiol

PMID:
24149024
PMCID:
PMC3947014
DOI:
10.1016/j.vascn.2013.10.004
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center